REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
Results of Operations and Financial Condition.
REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Results of Operations and Financial Condition
On August 8, 2017, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2017. The press release is furnished as Exhibit99.1 to this Current Report on Form8‑K and is incorporated by reference herein.
The information in Item 2.02 of this Current Report on Form8‑K and Exhibit99.1 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 2.02. |
Financial Statements and Exhibits. |
(d)Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated August 8, 2017 relating to REGENXBIO Inc.’s financial results. |
REGENXBIO Inc. ExhibitEX-99.1 2 rgnx-ex991_6.htm EX-99.1 rgnx-ex991_6.htm EXHIBIT 99.1 REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights • Enrollment continues in RGX-314 Phase I clinical trial for wet AMD; interim update anticipated by year-end 2017 • Enrollment continues in RGX-501 Phase I/II clinical trial for HoFH; interim update anticipated by year-end 2017 • IND active for third lead product candidate – RGX-111 for MPS I • $209 million in cash,…To view the full exhibit click here
About REGENXBIO INC. (NASDAQ:RGNX)
REGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).
